Program
ivonescimab
Also written as “AK112”, “Ivonescimab Injection” and “Ivonescimab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms · Small Cell Lung Carcinoma, led by 5 companies.
Drug pageIvonescimab: every studyMany companies study it; this page follows only the 48 they lead. All 147 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Akesoits history only | 3930 open or running | phase 3since Dec 21, 2021 | Aug 5, 2019 | Dec 2026phase 2 · NCT05689853 |
| Summit Therapeuticsits history only | 66 open or running | phase 3since Jun 1, 2023 | Jun 1, 2023 | Apr 2028phase 3 · NCT06767514 |
| GlaxoSmithKlineits history only | 11 open or running | phase 2since May 15, 2026 | May 15, 2026 | Jun 22, 2029phase 2 · NCT07602855 |
| Multitude Therapeutics | 11 open or running | phase 2since May 10, 2026 | May 10, 2026 | May 30, 2027phase 2 · NCT07590531 |
| Shanghai Allink Biotherapeuticsits history only | 11 open or running | phase 2since Jul 29, 2026 | Jul 29, 2026 | Dec 31, 2027phase 2 · NCT07742956 |
Also a collaborator on its studies: Shanghai Virogin Biotech.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseSummit Therapeutics licensed it from Akeso, for the US, Canada, Europe and Japan.Announced Dec 6, 2022 · Source: Summit Therapeutics (8-K exhibit), Dec 6, 2022
How GlaxoSmithKline, Multitude Therapeutics and Shanghai Allink Biotherapeutics relate to it is not in the registry or these sources.
History and studies of Multitude Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 28, 2021Named ivonescimabINNProposed as its International Nonproprietary Name in WHO's List 125 · before, AK112
- Dec 6, 2022Summit Therapeutics licensed it from AkesoLicenseThe US, Canada, Europe and Japan · announced · Summit Therapeutics (8-K exhibit)
- May 10, 2026First study: phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)First studyNCT07590531 · 118 planned · China
Ahead
- May 30, 2027Primary completion: phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)NCT07590531
TargetBeta
“A bispecific antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human vascular endothelial growth factor (VEGF), ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tivunatamig | Pfizer | phase 3 | 15 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody SCTB14rule | Sinocelltech Group | phase 3 | 2 |
| ABBV-1480 | RemeGen | phase 3 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001rule | Sichuan Kelun Pharmaceutical | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 | Merck | phase 2 | 4 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody MHB039Arule | Minghui Pharmaceutical | phase 2 | 3 |
| Anti-PD-1/Anti-VEGF Bispecific Antibody JS207rule | wigen-biomedicine-technology-shanghai-co-ltd | phase 2 | 2 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| Anti-PD-1/Anti-VEGF-A Bispecific Antibody CTX-10726rule | compass-therapeutics | phase 1 | 1 |
Studies
The one study Multitude Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07590531Advanced Non-small Cell Lung Cancer (NSCLC) · China | 2 | Recruiting | May 30, 2027 | 118 |
How it is read
Names in the registry
- “AK112”, 27 entries
- “Ivonescimab Injection”, 3 entries
- “Ivonescimab”, 3 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “AK112 Injection”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 14 studies
- Colorectal Neoplasms, 4 studies
- Ovarian Neoplasms, 3 studies
- Triple Negative Breast Neoplasms, 2 studies
- Small Cell Lung Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.